MyoKardia, a clinical-stage biotech developing therapies for heritable cardiomyopathies, announced terms for its IPO on Monday.
The South San Francisco, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, MyoKardia would command a fully diluted market value of $425 million.
MyoKardia, which was founded in 2012 and booked $13 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol MYOK. Credit Suisse and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of October 26, 2015.
